ATE445603T1 - Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung - Google Patents

Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung

Info

Publication number
ATE445603T1
ATE445603T1 AT02005248T AT02005248T ATE445603T1 AT E445603 T1 ATE445603 T1 AT E445603T1 AT 02005248 T AT02005248 T AT 02005248T AT 02005248 T AT02005248 T AT 02005248T AT E445603 T1 ATE445603 T1 AT E445603T1
Authority
AT
Austria
Prior art keywords
polymorphs
donepezil hydrochloride
production
peaks
hydrochloride
Prior art date
Application number
AT02005248T
Other languages
English (en)
Inventor
Hideaki Watanabe
Akio Imai
Takashi Kajima
Yasushi Ishihama
Akiyo Ohtsuka
Tomohide Tanaka
Yukio Nabaru
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15404413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445603(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE445603T1 publication Critical patent/ATE445603T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
AT02005248T 1996-06-07 1997-06-06 Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung ATE445603T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP14629396 1996-06-07
PCT/JP1996/003881 WO1997046526A1 (en) 1996-06-07 1996-12-27 Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US08/774,802 US6140321A (en) 1996-06-07 1996-12-30 Polymorphs of donepezil hydrochloride and process for production

Publications (1)

Publication Number Publication Date
ATE445603T1 true ATE445603T1 (de) 2009-10-15

Family

ID=15404413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02005248T ATE445603T1 (de) 1996-06-07 1997-06-06 Polymorphe von donepezil-hydrochlorid und verfahren zur herstellung

Country Status (16)

Country Link
US (1) US6140321A (de)
JP (2) JP2005015486A (de)
KR (1) KR100545851B1 (de)
CN (1) CN1312129C (de)
AT (1) ATE445603T1 (de)
AU (1) AU1153097A (de)
CA (1) CA2516108C (de)
DE (1) DE69739622D1 (de)
DK (1) DK1211243T3 (de)
ES (1) ES2330997T3 (de)
HU (1) HUP0900417A3 (de)
PT (1) PT1211243E (de)
SI (1) SI22888B (de)
UA (1) UA60307C2 (de)
WO (1) WO1997046526A1 (de)
ZA (1) ZA975064B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134263A (en) * 1997-08-21 2006-04-10 Gerolymatos P N Sa Pharmaceutical compositions containing phanquinone for the treatment of alzheimer's disease
JP2001517617A (ja) 1997-09-24 2001-10-09 ノヴァ モレキュラー インク. 神経変性疾患の治療を目的としてapoeレベルを増加させる方法
AU1792200A (en) 1999-01-07 2000-07-24 P.N. Gerolymatos S.A. Use of phanquinone for the treatment or prevention of memory impairment
US6677330B1 (en) 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
ES2288984T3 (es) 2000-09-25 2008-02-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento para producir un cristal polimorfico de hidrocloruro de donepezilo.
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
AU2003207184B2 (en) * 2002-02-07 2008-02-14 Eisai R And D Management Co., Ltd. Hair growth stimulants, percutaneous preparations and method of stimulating hair growth
ATE429452T1 (de) * 2002-05-01 2009-05-15 San Ei Gen Ffi Inc Verfahren zur modifizierung von gummi arabicum
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
IL154370A0 (en) * 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
US20050288330A1 (en) * 2004-06-29 2005-12-29 Avinash Naidu Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7560560B2 (en) * 2003-04-16 2009-07-14 Hetero Drugs Limited Crystalline forms of donepezil hydrochloride
WO2004099142A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
CA2566204A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
US20080114173A1 (en) * 2004-07-30 2008-05-15 Mathad Vijayavitthal Thippanna Crystalline Form of Donepezil Hydrochloride
US7371906B2 (en) * 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
AU2005289100B2 (en) * 2004-09-29 2011-11-03 Bayer Healthcare Llc Thermodynamically stable form of bay 43-9006 tosylate
AU2005288521A1 (en) * 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
EP2039349A1 (de) * 2004-10-19 2009-03-25 KRKA, tovarna zdravil, d.d., Novo mesto Feste pharmazeutische Zusammensetzung mit Donepezilhydrochlorid
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US20060122226A1 (en) * 2004-12-08 2006-06-08 Itai Adin Crystalline forms of Donepezil base
EP2425846A1 (de) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterasehemmer und Leuprolidacetat zur Behandlung von Alzheimer-Krankheit
JP5180816B2 (ja) * 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
WO2007018801A1 (en) * 2005-07-28 2007-02-15 Teikoku Pharma Usa, Inc. Gelled donepezil compositions and methods for making and using the same
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7274339B2 (en) * 2005-09-16 2007-09-25 Smartant Telecom Co., Ltd. Dual-band multi-mode array antenna
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR063319A1 (es) * 2006-10-16 2009-01-21 Medichem Sa Proceso mejorado para preparar la forma polimorfica i de clorhidrato de donepezilo (2,3-dihidro-5,6-dimetoxi-2-[[1-(fenilmetil)-4-piperidin]metil-1h-inden-1-ona)
EP2420235A1 (de) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Verfahren und Kombinationstherapien zur Behandlung von Alzheimer
WO2008055629A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 4−[4−({[4−クロロ−3−(トリフルオロメチル)フェニル]カルバモイル}アミノ)−3−フルオロフェノキシ]−n−メチルピリジン−2−カルボキサミドの多形ii
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
WO2008139984A1 (en) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
WO2009084030A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd. Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP5488956B2 (ja) * 2008-11-25 2014-05-14 株式会社Dnpファインケミカル宇都宮 (±)2−(ジメチルアミノ)−1−{〔O−(m−メトキシフェネチル)フェノキシ〕メチル}エチル水素サクシナート塩酸塩のI形結晶とII形結晶の混晶の製造法
EP2382216A1 (de) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salzformen einer organischen verbindung
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
WO2011061591A1 (en) 2009-11-18 2011-05-26 Jubilant Life Sciences Limited Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
EP2533645B1 (de) 2010-02-09 2016-07-27 The Johns Hopkins University Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
CA2795559A1 (en) * 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
WO2012053016A1 (en) 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (de) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103012247B (zh) * 2013-01-18 2014-12-10 浙江东亚药业有限公司 一种盐酸多奈哌齐无水i晶型的制备方法
CN103965188A (zh) * 2013-01-29 2014-08-06 中山大学 含硒多奈哌齐类似物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN106397306B (zh) * 2016-10-20 2019-03-08 山东罗欣药业集团股份有限公司 一种盐酸多奈哌齐晶型化合物及其制备方法
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
IL288505B1 (en) 2019-05-31 2026-07-01 Tecnimede Sociedade Tecnico Medicinal Sa Immediate release fixed dose memantine and donepezil
CN120513081A (zh) 2022-12-28 2025-08-19 考里安有限责任公司 制备透皮递送系统的方法
EP4642432A1 (de) 2022-12-28 2025-11-05 Corium, LLC Vormischungsverfahren zur herstellung eines transdermalen abgabesystems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi

Also Published As

Publication number Publication date
UA60307C2 (uk) 2003-10-15
JP2009040783A (ja) 2009-02-26
WO1997046526A1 (en) 1997-12-11
US6140321A (en) 2000-10-31
SI22888B (sl) 2010-06-30
DE69739622D1 (de) 2009-11-26
ZA975064B (en) 1998-04-01
DK1211243T3 (da) 2010-02-08
HUP0900417A3 (en) 2012-12-28
HU0900417D0 (en) 2009-08-28
PT1211243E (pt) 2009-11-06
SI22888A (sl) 2010-04-30
CA2516108A1 (en) 1997-12-11
JP2005015486A (ja) 2005-01-20
HK1080078A1 (en) 2006-04-21
CN1312129C (zh) 2007-04-25
CN1699343A (zh) 2005-11-23
AU1153097A (en) 1998-01-05
ES2330997T3 (es) 2009-12-18
KR100545851B1 (ko) 2006-01-24
KR20040104707A (ko) 2004-12-10
CA2516108C (en) 2008-12-02

Similar Documents

Publication Publication Date Title
DE69739622D1 (de) Polymorphe von Donepezil-Hydrochlorid und Verfahren zur Herstellung
CA2252806A1 (en) Polymorphs of donepezil hydrochloride and process for production
DE59306172D1 (de) Flammenhydrolytisch hergestelltes Titandioxid-Mischoxid, Verfahren zu seiner Herstellung und Verwendung
DE69618515D1 (de) Geriffelter teig und verfahren zur herstellung des geriffelten teigs
DE69739561D1 (de) Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
NO982712D0 (no) FremgangsmÕter og mellomprodukter for fremstilling av 1-benzyl-4-((5,6-dimetoksy-1-indanon)-2-yl)metylpiperidin
ATE220667T1 (de) Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon
DE69506431D1 (de) Stärkeprodukte als tablettierhilfstoff, verfahren zu deren herstellung und verfahren zur herstellung von tabletten
ATE230396T1 (de) Polymorphe von donepezyl-hydrochlorid und verfahren zur herstellung
NO970023D0 (no) Fremgangsmåte for fremstilling av en anatase-titandioksyd, og anatase-titandioksyd oppnådd derved
PL1761492T3 (pl) Szczawian 1-benzylo-4-[(5,6-dimetoksy-1-indanon)-2-ylo]metylopiperydyny (szczawian donepezilu) i jego polimorfy
DE69300062D1 (de) Verfahren zur Herstellung von N-Methoxyderivate von 4-Hydroxy-2,2,6,6-Tetramethylpiperidin und 2,2,6,6-Tetramethyl-4-Piperidon.
DE69628540D1 (de) Racemisierungsverfahren zur herstellung von levobupivacain und verwandte piperidin carboxanilide mit anästhetischer wirkung
DE69703554D1 (de) VERFAHREN ZUR HERSTELLUNG VON N- (1-n-BUTYL-4-PIPERIDINYL)METHYL] -3,4-DIHYDRO -2H-[1,3]OXAZINO[3,2-a]INDOL-10-CARBOXAMID UND SALZE SOWIE ZWISCHENPRODUKTE IN DEM VERFAHREN
DE59500256D1 (de) Verfahren zum Herstellen von Superisolierungspaneelen und Superisolierungspaneele selbst, sowie ihre Verwendung
NO20002450L (no) Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type
ATE140455T1 (de) Neue 2-amino-5-cyano-1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
HU9800511D0 (en) Process for producing 4-{4-[4-(hydroxy-diphenyl)-1-piperidinyl]-1-hydroxy-butyl}-alpha-alpha-dimethyl-phenyl-acetic.acid and phosphorylized derivatives thereof
HUP0002270A2 (hu) Donepezil-hidroklorid polimorf módosulatai, eljárás ezek előállítására, valamint e módosulatokat tartalmazó gyógyászati készítmények
FI885254A7 (fi) Menetelmä titaanidioksidin valmistamiseksi hajottamalla titaanikuonapitoista lähtöainetta ja ilmeniittiä
PT86211A (de) Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
PL303978A1 (en) Novel derivatives of piperidine and piperazine, method of obtaining them as well as pharmaceutical preparation and method of obtaining same
DE69618486D1 (de) Verfahren zum herstellen von riechstoffkompositionen und riechstoffprodukten und so erhaltene produkte
FI941480L (fi) 1,2,5,6-tetrahydropyridiinijohdannainen, menetelmä sen valmistamiseksi ja sen käyttö terapiassa
FI92578C (fi) Menetelmä titaanidioksidin valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1211243

Country of ref document: EP